Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Inching toward a serogroup B meningococcal vaccine for infants.

Cohn AC, Messonnier NE.

JAMA. 2012 Feb 8;307(6):614-5. doi: 10.1001/jama.2012.118. No abstract available.

PMID:
22318284
2.

Evolving meningococcal immunization strategies.

Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R; Global Meningococcal Initiative.

Expert Rev Vaccines. 2015 Apr;14(4):505-17. doi: 10.1586/14760584.2015.979799. Epub 2014 Dec 10. Review.

PMID:
25494168
3.

A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

Martin NG, Snape MD.

Expert Rev Vaccines. 2013 Aug;12(8):837-58. doi: 10.1586/14760584.2013.814862. Review.

PMID:
23984957
4.

[Meningococcal vaccines: from polysaccharide to conjugate vaccines].

Cohen R, Levy C.

Arch Pediatr. 2012 Sep;19 Suppl 2:S61-4. doi: 10.1016/S0929-693X(12)71275-7. French.

PMID:
22883368
5.

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group.

JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85.

PMID:
22318278
6.

A routine infant schedule versus an older infant/toddler schedule for Neisseria meningitidis vaccination: what do experience and reason tell us?

Black S, Shinefield H.

Expert Rev Vaccines. 2009 Dec;8(12):1623-6. doi: 10.1586/erv.09.124. Review. No abstract available.

PMID:
19943757
7.

Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.

Carter NJ.

BioDrugs. 2013 Jun;27(3):263-74. doi: 10.1007/s40259-013-0029-2. Review.

PMID:
23575646
8.

Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.

Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT.

Vaccine. 2015 Jan 1;33(1):268-75. doi: 10.1016/j.vaccine.2013.09.034. Epub 2013 Oct 6.

9.

Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR; Centers for Disease Control (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Jun 12;64(22):608-12. Erratum in: MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):806.

10.

Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.

Omeñaca F, Arístegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J, Merino JM, Muro Brussi M, Sánchez-Tamayo T, Castro Fernandez J, Cabanillas L, Peddiraju K, Mesaros N, Miller JM.

Pediatr Infect Dis J. 2011 Nov;30(11):e216-24. doi: 10.1097/INF.0b013e3182293a82.

PMID:
21747321
11.

Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.

McVernon J, MacLennan J, Pollard AJ, Oster P, Wakefield MJ, Danzig L, Moxon ER.

Pediatr Infect Dis J. 2003 Jul;22(7):659-61.

PMID:
12886896
12.

A multivalent conjugate vaccine for prevention of meningococcal disease in infants.

Harrison LH.

JAMA. 2008 Jan 9;299(2):217-9. doi: 10.1001/jama.2007.57-c. No abstract available.

PMID:
18182606
13.

A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.

Pace D, Snape M, Westcar S, Hamaluba M, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, Pollard AJ.

Pediatr Infect Dis J. 2007 Nov;26(11):1057-9.

PMID:
17984816
14.

Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.

Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, Cuevas I, Carbonero M, Campa HC, Sierra G, Levin M.

Pediatr Infect Dis J. 2001 Nov;20(11):1054-61.

PMID:
11734711
15.

The challenge of post-implementation surveillance for novel meningococcal vaccines.

Snape MD, Medini D, Halperin SA, DeTora L, Drori J, Moxon ER.

Vaccine. 2012 May 30;30 Suppl 2:B67-72. doi: 10.1016/j.vaccine.2011.12.126. Epub 2012 Jan 9. Review.

PMID:
22230578
16.

Serogroup A meningococcal conjugate vaccines in Africa.

Kristiansen PA, Jørgensen HJ, Caugant DA.

Expert Rev Vaccines. 2015;14(11):1441-58. doi: 10.1586/14760584.2015.1084232. Epub 2015 Aug 31. Review.

PMID:
26358167
17.

Meningococcal vaccines: current issues and future strategies.

Cohn AC, Harrison LH.

Drugs. 2013 Jul;73(11):1147-55. doi: 10.1007/s40265-013-0079-2. Review.

PMID:
23839656
18.

Prevention of meningococcal infections in the first 2 years of life.

Woods CR.

Pediatr Ann. 2013 Aug;42(8):164-71. doi: 10.3928/00904481-20130723-11. Review.

PMID:
23910030
19.

Considerations for controlling invasive meningococcal disease in high income countries.

Holst J, Nøkleby H, Bettinger JA.

Vaccine. 2012 May 30;30 Suppl 2:B57-62. doi: 10.1016/j.vaccine.2011.12.093. Review.

PMID:
22607900
20.

MenB candidate vaccine Bexsero induces robust immune response in infants.

Riedmann EM.

Hum Vaccin Immunother. 2012 Mar;8(3):282. No abstract available.

PMID:
23213659

Supplemental Content

Support Center